Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.

The American journal of clinical nutrition·2026
Same author

Plasma metabolomics and red blood cell fatty acid profiles in adolescent mental health.

Comprehensive psychoneuroendocrinology·2026
Same author

Dietary Choline and Betaine Intake and 2-year Changes in Cognitive Function in Older Adults With Overweight or Obesity and Metabolic Syndrome: A Prospective Cohort Analysis.

The American journal of clinical nutrition·2026
Same author

Loss of energy homeostasis contributes to hepatic damage development in sickle cell disease.

Molecular metabolism·2026
Same author

Opposing functions of miR-155-5p and Socs1 drive vascular inflammation in diabetes-accelerated atherosclerosis.

Cardiovascular diabetology·2026
Same author

Development of a blood-based lipidomic fat quality score for the risk of ischemic stroke.

European stroke journal·2026

Related Experiment Video

Updated: May 24, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study.

Anna Cabré1, Nancy Babio, Iolanda Lázaro

  • 1Research Unit on Lipids and Atherosclerosis, CIBERDEM, Spain.

Atherosclerosis
|March 17, 2012
PubMed
Summary

Elevated adipocyte fatty acid-binding protein (FABP4) may predict the development of atherogenic dyslipidemia (AD). This risk was particularly noted in women, suggesting FABP4 as a potential marker for metabolic derangement.

More Related Videos

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker
13:26

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker

Published on: March 31, 2018

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Experiment Videos

Last Updated: May 24, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker
13:26

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker

Published on: March 31, 2018

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Area of Science:

  • Cardiovascular Disease
  • Metabolic Syndrome
  • Endocrinology

Background:

  • Atherogenic dyslipidemia (AD) is a key factor in vascular damage linked to obesity, metabolic syndrome (MS), and type 2 diabetes.
  • Adipocyte fatty acid-binding protein (FABP4) is associated with metabolic alterations and adiposity.

Purpose of the Study:

  • To prospectively evaluate the predictive value of baseline plasma FABP4 concentrations for the development of AD.

Main Methods:

  • Prospective analysis of baseline plasma FABP4 levels and AD incidence over six years.
  • Study conducted within the PREDIMED multicenter dietary interventional trial.
  • Involved 578 volunteers with cardiovascular risk factors.

Main Results:

  • 103 participants developed AD during follow-up.
  • Baseline FABP4 levels predicted new-onset AD (OR 1.03, p=0.020).
  • Increased risk was significant in women, with the highest FABP4 tertile showing a 2.54-fold increased relative risk (HR 2.54, p=0.008).

Conclusions:

  • Elevated plasma FABP4 concentrations may serve as a marker for metabolic derangement.
  • FABP4 has potential as a predictor for AD development, especially in women.